rejuvant life tabs

Turn Bio expands mRNA platform with artificial niche tech

Latest articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...
Rejuvant

Turn Biotechnologies expands the potential of its mRNA platform by licensing unique artificial niche technology.

Turn Biotechnologies announced today that it has acquired the global rights for new artificial niche (AN) technology that can be used to restore muscle stem cells damaged by aging.

Longevity.Technology: California-based Turn develops medicines for currently untreatable age-related conditions. Today’s announcement is hot on the heels of last month’s news that it has acquired the global rights for ERA (epigenetic reprogramming of age) tech, which unwind the effects of aging at a cellular level. After Turn’s success with Yamanaka factors last year, this biotech seems to be going from strength to strength.

The company licensed its AN technology from Stanford University where it was developed by a researcher who serves as an advisor to Turn. AN technology is used to create a microenvironment that maintains stem cells in a quiescent state to repair or replace specific types of damaged tissue. The stem cell niche provides structural and trophic support and the appropriate homeostasis to regulate stem cell function.

 


 

“… By enveloping our ERA technology in the protective matrix of an artificial niche, we can reactivate muscle stem cells, as well as stem cells in tissues …”

 


 

Turn will use the niche technology in combination with its mRNA-based epigenetic reprogramming of age (ERA™) technology to restore specific cells’ youthful functionality, to trigger the body’s ability to fight age-related diseases.

“Our artificial niche technology expands the applicability of our ERA technology to a variety of diseases involving tissue that requires a microenvironment to maintain cell quiescence,” said Anja Krammer, Turn CEO. “By enveloping our ERA technology in the protective matrix of an artificial niche, we can reactivate muscle stem cells, as well as stem cells in tissues where quiescence is necessary to maintain stem cell functions.”

The artificial niche replicates the environment of muscle stem cells through enriched media and structural support via engineered muscle fibers (EMFs). This confocal microscopy image shows how EMFs replicate the shape and collagen content (green) of a muscle fiber (myofiber) to tether isolated muscle stem cells (blue). High resolution electron micrographs on right confirm muscle stem cell anchoring. (Source: Turn Biotechnologies). Source: Turn Biotechnologies

Elevant

The combined use of Turn’s AN and ERA technologies may be able to restore function in hematopoietic, liver, brain, certain mesenchymal stem cells across different tissues and within the hair follicle.

 


 

“… aged muscle stem cells treated with this combination therapy fully regenerate age-related muscle dysfunctions.”

 


 

As with ERA, Turn Bio announced that it has filed for patents to protect its AN technology in major-market nations on six continents.

“This is significant for our pipeline because the combination of AN with our ERA technology in murine models shows increased potency,” said Jay Sarkar, Turn’s chief technology officer and a company founder who helped to develop the ERA technology. “The studies show that aged muscle stem cells treated with this combination therapy fully regenerate age-related muscle dysfunctions.”

Turn’s technology uses messenger RNA to produce instructions that induce cells to treat or prevent disease. Use of mRNA, which led to the quick development of two COVID-19 vaccines, promises to revolutionize the development of therapeutics by making that development safer, faster, more efficient and extremely tuneable to patient need.

Elevant

Turn has financial backing from the Methuselah Fund, Formic Ventures and Shanda Group; the company is currently completing pre-clinical research on tailored therapies targeting indications in dermatology, ophthalmology, osteo-arthritis and cartilage damage and musculature.

Images courtesy of Turn Biotechnologies

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

New perspective in gerontology: epigenetic rejuvenation

Can biological age be set back by "making the clock tick backwards"? Scientists suggest that a partial phenotypic rejuvenation can be gained. Since the discovery...

BioAge licenses Amgen drug to treat muscle aging

Exclusive deal to develop and commercialise Amgen’s Phase 1 APJ agonist, after BioAge platform identifies its potential in promoting longevity and reducing symptoms of...

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...
Supps report ad middle